Trust Signals
Key Takeaways
- Tesamorelin is the only GH-releasing peptide with FDA approval (for HIV-related lipodystrophy) and has demonstrated IGF-1 increases of roughly 70 to 180 mcg/L above baseline in Phase III trials.
- Ipamorelin is a selective GHSR-1a agonist that produces significantly less cortisol and prolactin elevation than first-generation GHRPs like GHRP-6 at comparable GH-releasing doses, based on preclinical and early human pharmacology data.
- Combining a GHRH analog with a GHRP (for example, CJC-1295 with ipamorelin) produces synergistic GH release because the two classes act on different receptors simultaneously.
- CJC-1295 with DAC has a half-life of roughly 6 to 8 days due to albumin binding via a maleimide linkage, creating continuous rather than pulsatile GH stimulation, which is pharmacologically distinct from sermorelin.
- MK-677 is the only oral option in this class and has the most human trial data outside tesamorelin, but it consistently raises fasting glucose and increases appetite, which limits its use in metabolic risk populations.
What Is the Best Peptide for Growth Hormone?
Tesamorelin has the strongest human RCT evidence for clinically meaningful GH-axis outcomes. For well-tolerated GH pulse amplification without a prescription drug context, ipamorelin combined with a GHRH analog such as CJC-1295 (without DAC) is the most studied non-approved protocol. No single peptide is best for every goal: the answer depends on your target outcome, route tolerance, and risk profile.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
How Do GH-Releasing Peptides Actually Work?
The pituitary releases GH in response to two opposing signals from the hypothalamus: growth hormone-releasing hormone (GHRH) stimulates release, and somatostatin inhibits it. A separate pathway, the ghrelin receptor (GHSR-1a), amplifies GH pulse amplitude independently of GHRH.
GH-releasing peptides fall into two functional classes that exploit these pathways:
- GHRH analogs (sermorelin, CJC-1295, tesamorelin): bind the pituitary GHRH receptor to stimulate GH synthesis and release. They require an intact pituitary and are blunted when somatostatin tone is high.
- Ghrelin mimetics / GHRPs (ipamorelin, hexarelin, GHRP-2, GHRP-6, MK-677): bind GHSR-1a on pituitary somatotrophs and in the hypothalamus, suppressing somatostatin and amplifying pulse amplitude. They work even during high somatostatin tone.
This mechanistic difference explains why combining one from each class produces additive to synergistic GH elevation, a principle confirmed in pharmacology studies.
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces visceral adipose tissue in HIV lipodystrophy | Multiple Phase III human RCTs (Falutz et al., Hadigan et al.) | Positive (significant reduction) | High |
| Tesamorelin raises IGF-1 above baseline | Phase III RCTs | Positive | High |
| MK-677 raises GH and IGF-1 in healthy adults and elderly | Multiple human RCTs (Thorner et al., Chapman et al.) | Positive | High (for GH/IGF-1 elevation); Moderate (for functional outcomes) |
| MK-677 raises fasting glucose | Human RCTs | Negative (insulin resistance signal) | High |
| Ipamorelin is more selective (less cortisol/prolactin) than GHRP-6 | Animal studies, small human pharmacology data | Positive (selectivity advantage) | Moderate |
| CJC-1295 with DAC elevates GH/IGF-1 for days after a single dose | One small human PK study (Ionescu and Frohman, 2006) | Positive | Moderate (small n) |
| Sermorelin preserves physiological GH pulsatility | Mechanism and small human PK studies | Positive (mechanism-supported) | Moderate (large RCTs lacking) |
| GHRH/GHRP combination produces synergistic GH release | Human pharmacology studies | Positive | Moderate |
| GH-releasing peptides improve muscle mass or athletic performance in healthy adults | Limited, mostly animal or small human pilot | Uncertain | Low |
| GH-releasing peptides are safe long-term in healthy humans | No long-term RCTs in non-approved populations | Unknown | Very Low |
The Best Peptides for Growth Hormone, Ranked
1. Tesamorelin
The only FDA-approved GH-releasing peptide. A 44-amino-acid GHRH analog stabilized with a trans-3-hexenoic acid group at the N-terminus that protects it from dipeptidyl peptidase IV (DPP-IV) cleavage. Phase III trials in HIV-associated lipodystrophy showed statistically significant visceral fat reduction and IGF-1 elevation. If evidence grade is your primary criterion, tesamorelin is first.
Limitation: Approved only for a specific population. Off-label use in healthy individuals lacks large-trial safety data.
2. Ipamorelin
A pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the most selective GHSR-1a agonist in clinical research use. Its selectivity for GH release over ACTH and prolactin release makes it the preferred GHRP for protocols where cortisol and water retention are concerns. Half-life is short (roughly 2 hours in animal studies), so it produces discrete pulses rather than sustained elevation.
Best paired with: A GHRH analog for synergistic effect.
3. CJC-1295 (without DAC) / Modified GRF(1-29)
A 29-amino-acid GHRH fragment with four amino acid substitutions that resist DPP-IV degradation, extending its half-life from the 2 to 3 minutes of native GHRH to roughly 30 minutes. This longer window produces a more physiological GH pulse compared to CJC-1295 with DAC. Many researchers consider this the preferred GHRH analog for pulsatile protocols.
4. Sermorelin
The first 29 amino acids of native GHRH. It was previously FDA-approved for pediatric GH deficiency diagnosis and treatment (though the original approval was withdrawn for commercial reasons, not safety). Sermorelin has a short half-life (roughly 10 to 20 minutes) and preserves the normal feedback relationship between the pituitary and hypothalamus most closely of any peptide in this list.
Best for: Those prioritizing physiological patterning and an established human safety record.
5. CJC-1295 with DAC
The same GHRH analog backbone with a Drug Affinity Complex that covalently binds albumin, extending half-life to roughly 6 to 8 days (Ionescu and Frohman, 2006). This creates a tonic rather than pulsatile GH signal. Whether sustained GH elevation produces better or worse outcomes than pulsatile release, and whether it increases risk of GH-related adverse effects, is not resolved in the literature.
Ranked 5th because: The pharmacokinetic profile is the most physiologically deviant of the GHRH analogs, and long-term consequences are unstudied.
6. MK-677 (Ibutamoren)
Not a peptide. A small molecule, non-peptide ghrelin mimetic that is orally bioavailable. Oral bioavailability is a genuine advantage over all injectable peptides. Multiple human RCTs confirm GH and IGF-1 elevation. However, human trials also consistently document fasting glucose increases and substantial appetite stimulation, which are not seen at the same frequency with injectable selective GHRPs. Ranked 6th due to metabolic risk signals and the fact that it is pharmacologically distinct from the peptides above.
Mechanism With Numbers: What the Data Actually Shows
Tesamorelin in the Falutz et al. (2010) Phase III trial (271 HIV-positive participants) produced a mean IGF-1 increase of approximately 70 to 180 mcg/L above baseline depending on the trial arm, with visceral adipose tissue reduction confirmed by CT scan. These are real, endpoint-validated numbers in a defined population.
MK-677 in the Chapman et al. (1996) study of 32 healthy young adults produced a roughly 40 to 100 percent increase in 24-hour mean GH concentration and IGF-1 normalization in those starting with low IGF-1. However, fasting glucose increased by an average of roughly 0.3 mmol/L and insulin sensitivity declined.
CJC-1295 with DAC in the Ionescu and Frohman (2006) study (n=40 healthy adults) showed mean GH increases of 2 to 10-fold and IGF-1 increases of 1.5 to 3-fold over baseline, persisting for 6 days after a single injection.
What these numbers do NOT prove: None of these GH or IGF-1 elevations have been directly linked to improved muscle mass, longevity, or athletic performance in large, pre-registered RCTs in healthy adults. GH and IGF-1 are surrogate endpoints. The clinical benefit in non-deficient individuals is genuinely unproven.
What Most Pages Get Wrong
Peptides do not survive oral administration. Sermorelin, ipamorelin, CJC-1295, and tesamorelin are all peptides that are rapidly cleaved by gastric proteases and DPP-IV in the gut lumen. "Oral peptide" products containing these sequences are not delivering intact peptide to the circulation. Subcutaneous injection is the only validated delivery route for these compounds. Any product claiming oral delivery of an injectable peptide without a demonstrated oral bioavailability figure from a peer-reviewed human PK study should be treated skeptically.
Purity and sourcing reality: Research-grade peptides sold by unlicensed suppliers have no mandatory purity verification. Independent analyses of research peptide samples have found incorrect sequences, truncated fragments, and bacterial endotoxins. A compound that is 70 to 80 percent pure at the peptide level means 20 to 30 percent of what is injected is an unknown substance. Absence of a certificate of analysis from an accredited third-party laboratory is disqualifying.
The CJC-1295 naming confusion: Many suppliers and forums use "CJC-1295" to refer to either the DAC or non-DAC version interchangeably. These are pharmacokinetically very different compounds. Always confirm with the supplier whether DAC is present.
Chemistry Behind the Rules
Why store cold and use quickly after reconstitution? Peptide bonds are susceptible to hydrolysis in aqueous solution, particularly at elevated temperatures. Aggregation (where peptide chains clump together into non-functional clusters) accelerates with heat and repeated freeze-thaw cycles because denaturation exposes hydrophobic residues that then interact with each other. In solution, oxidation of methionine residues (present in GHRH analogs) by dissolved oxygen contributes to loss of receptor binding affinity over time. Using bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative) slows microbial degradation but does not stop chemical degradation. This is why a reconstituted peptide is not equivalent to lyophilized powder even when stored at the same temperature.
Why DPP-IV resistance matters: Native GHRH(1-44) has a half-life of roughly 2 to 3 minutes because the DPP-IV enzyme cleaves the Ala-Gly bond at positions 2 to 3, inactivating it. Sermorelin (GHRH 1-29) retains this cleavage site and has a similarly short half-life. Modified GRF(1-29) / CJC-1295 without DAC substitutes amino acids at positions 2, 8, 15, and 27 specifically to resist DPP-IV cleavage at position 2, extending the active window to roughly 30 minutes. Tesamorelin adds a trans-3-hexenoic acid group at the N-terminus to achieve the same protection. Understanding this tells you why older formulations required frequent dosing and why newer analogs are more practical.
Honest Head-to-Head Table
| Peptide | Class | Half-Life | Best Evidence | Main Advantage | Main Disadvantage | vs. Synthetic GH (rhGH) |
|---|---|---|---|---|---|---|
| Tesamorelin | GHRH analog | ~26 min (active; DAA-protected) | Phase III RCTs | FDA-approved, proven VAT reduction | Approved for one narrow indication; expensive | Loses on potency; wins on pituitary feedback preservation |
| Ipamorelin | Ghrelin mimetic / GHRP | ~2 hr (animal data) | Preclinical + small human PK | Selectivity; low cortisol/prolactin signal | No large human RCTs; no approved status | Loses on strength; wins on side effect profile vs. rhGH |
| CJC-1295 (no DAC) | GHRH analog | ~30 min | Mechanism; small PK studies | Physiological pulsatility; DPP-IV resistant | No large human RCTs | Loses on potency; preserves pulsatility unlike rhGH |
| Sermorelin | GHRH analog | ~10 to 20 min | Historical human studies; former FDA status | Established human safety record; physiological | Short half-life; less potent than newer analogs | Loses on potency; most physiological of all options |
| CJC-1295 with DAC | GHRH analog (long-acting) | ~6 to 8 days | One small human PK study | Infrequent dosing | Non-physiological tonic GH; poorly studied long term | Loses on evidence; wins on convenience vs. daily rhGH |
| MK-677 | Non-peptide ghrelin mimetic | ~24 hr | Multiple human RCTs | Oral; once daily; strong IGF-1 data | Raises fasting glucose; appetite increase; not a peptide | Oral vs. injectable is MK-677's only win |
| rhGH (Somatropin) | Synthetic GH (not a peptide) | ~3 to 5 hr (sc) | Multiple RCTs; FDA-approved | Most potent GH elevation | Bypasses pituitary feedback; higher side effect risk; scheduled drug | Reference compound; GH-releasing peptides are indirect alternatives |
Dosing, Product Selection, and Label Literacy
Dosing Reference Table (Research Protocols Only)
| Peptide | Typical Research Dose | Route | Timing | Frequency |
|---|---|---|---|---|
| Tesamorelin | 2 mg | Subcutaneous | Anytime (approved protocol) | Once daily (approved use) |
| Ipamorelin | 200 to 300 mcg | Subcutaneous | Pre-sleep or fasted | 1 to 3x daily |
| CJC-1295 (no DAC) | 100 to 200 mcg | Subcutaneous | Same time as ipamorelin | 1 to 3x daily |
| Sermorelin | 200 to 500 mcg | Subcutaneous | Pre-sleep | Once daily |
| CJC-1295 with DAC | 1 to 2 mg | Subcutaneous | No timing constraint | Once weekly |
| MK-677 | 10 to 25 mg | Oral | Evening (to blunt appetite effects) | Once daily |
How to Read a COA for a Peptide Product
A legitimate certificate of analysis from an accredited third-party lab should include: purity by HPLC (ideally above 98 percent), molecular weight confirmation by mass spectrometry matching the expected sequence, and ideally endotoxin testing (LAL assay, target below 5 EU/kg/dose for injectable use). If the COA is from the same company selling the product, it is not independent. If there is no COA, do not inject the compound.
What to look for on a reconstituted product: A properly reconstituted lyophilized peptide in bacteriostatic water should be clear and colorless. Cloudiness, particulate matter, or any yellow to brown discoloration indicates aggregation or degradation. Discard immediately. The reconstituted volume should match your calculation: if you add 2 mL to a 5 mg vial, each 0.1 mL (10 units on an insulin syringe) contains 250 mcg.
Frequently Asked Questions
What is the best peptide for growth hormone release?
Tesamorelin has the strongest human RCT evidence for raising IGF-1 and reducing visceral fat. For general GH pulse amplification, CJC-1295 with DAC or ipamorelin are most commonly studied. The best choice depends on your goal: tesamorelin for metabolic outcomes, ipamorelin for tolerability and pulse purity, sermorelin for physiological patterning.
What is the difference between a GHRH and a GHRP?
GHRH analogs (sermorelin, CJC-1295, tesamorelin) mimic the hypothalamic signal that tells the pituitary to make GH. GHRPs and ghrelin mimetics (ipamorelin, hexarelin, MK-677) act on the ghrelin receptor (GHSR-1a) to amplify GH pulse amplitude. Combining one from each class produces a synergistic GH release roughly double what either achieves alone.
Does ipamorelin raise cortisol or prolactin?
Preclinical and early human data suggest ipamorelin is more selective than older GHRPs like GHRP-6, producing less cortisol and prolactin elevation at GH-releasing doses. GHRP-6 and hexarelin both raise cortisol and prolactin at standard doses. Ipamorelin's selectivity is its main clinical advantage, though confirmatory large-scale human RCTs are limited.
Is sermorelin the same as growth hormone?
No. Sermorelin is a 29-amino-acid GHRH analog that signals the pituitary to release its own stored GH. It does not supply exogenous GH directly. This means GH release remains subject to normal pituitary feedback, which is considered a safety advantage over injecting synthetic GH.
Can you take MK-677 orally instead of injecting peptides?
Yes. MK-677 (ibutamoren) is a non-peptide ghrelin mimetic that is orally bioavailable, unlike injectable peptides that are degraded in the GI tract. It has documented GH and IGF-1 elevation in multiple human trials. However, it also raises fasting glucose, causes water retention, and significantly increases appetite, which limits tolerability.
What does CJC-1295 with DAC do differently from sermorelin?
CJC-1295 with DAC binds albumin via a maleimide linkage, extending its half-life from minutes to roughly 6 to 8 days. This creates a sustained elevation in basal GH rather than discrete physiological pulses. Whether a constant GH signal is preferable to pulsatile release for safety and efficacy is genuinely debated.
How do you store reconstituted growth hormone peptides?
Lyophilized peptides should be stored at 2 to 8 degrees Celsius and used within the manufacturer's stated shelf life. After reconstitution with bacteriostatic water, most peptides degrade meaningfully within 2 to 4 weeks at refrigerator temperature. Freeze-thaw cycling accelerates aggregation. Never use a reconstituted peptide that appears cloudy or has visible particulate.
What is tesamorelin approved for?
Tesamorelin (Egrifta) is FDA-approved specifically for reducing excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Its approval is based on multiple Phase III RCTs showing visceral adipose tissue reduction. It is not approved for general anti-aging, body composition, or athletic performance purposes.
What is the typical dose of ipamorelin?
Research protocols commonly use 200 to 300 micrograms of ipamorelin injected subcutaneously, typically at night to align with natural GH pulsatility. This dose range is derived from preclinical and small human pharmacology studies, not large Phase III trials. Dosing outside a supervised clinical protocol carries risk.
Are growth hormone peptides legal to buy?
In the United States, most GH-releasing peptides are classified as research chemicals or require a prescription as compounded medications. Tesamorelin requires a prescription. GHRP and GHRH analogs sold as research compounds are not approved for human use by the FDA. Regulations vary by country. WADA bans all GH-releasing peptides in sport.
What does a degraded peptide look like?
Degraded peptide in solution often appears cloudy, develops visible particles, or shows a color change from clear to yellow or brown. Lyophilized powder that has been temperature-abused may no longer dissolve cleanly. These are signs of aggregation or oxidation. A degraded peptide may be inactive or produce unpredictable immune responses.
Sources
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a 26-week extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257.
- Thorner MO, et al. Acceleration of growth and of skeletal maturation in children with short stature and GH deficiency by treatment with GH-releasing peptide. J Clin Endocrinol Metab. (Various GHRP mechanistic publications, PMC-indexed.)
- Bowers CY. GH releasing peptides: structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21-31.
- Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol. 1998;19(1):47-72.
- U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information. NDA 022505. Available at fda.gov.
- World Anti-Doping Agency (WADA). Prohibited List 2024: Section S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. Available at wada-ama.org.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.